Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location

Laura S. Gold, Ryan N. Hansen, Sonya L. Heltshe, Patrick A. Flume, Christopher H. Goss, Natalie E. West, Don B. Sanders, Larry Kessler

Research output: Contribution to journalArticlepeer-review

Abstract

Previous studies indicate that hospital rather than home treatment of pulmonary exacerbations (PEx) in people with cystic fibrosis (CF) can improve outcomes. We evaluated characteristics of adult participants from the Standardized Treatment of Pulmonary Exacerbations (STOP2) trial with two separate comparisons: (1) those who were treated initially in hospital (N = 768) to those treated initially at home (N = 214) and (2) those treated only in hospital (N = 328) to those who were treated only at home or both at home and in hospital (N = 654). Participants who had Medicaid insurance, were treated for shorter duration, and traveled longer to reach treatment centers were more likely to have been treated initially in the hospital. Having Medicaid insurance, being treated for a shorter duration, and being male were associated with being treated only in the hospital. This analysis suggests decisions about the location of treatment are based on pragmatic factors rather than on clinical characteristics.

Original languageEnglish (US)
Pages (from-to)278-281
Number of pages4
JournalJournal of Cystic Fibrosis
Volume23
Issue number2
DOIs
StatePublished - Mar 2024

Keywords

  • Cystic fibrosis
  • Home intravenous treatment
  • Hospitalization
  • Insurance
  • Pulmonary exacerbation
  • Sex

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location'. Together they form a unique fingerprint.

Cite this